[{"quiz_id": "20251216T183904770Z_deepseek-v3.2_seed131", "question_id": "20251216T183904770Z_deepseek-v3.2_seed131-001", "question": "A 58-year-old man with metastatic castration-resistant prostate cancer (mCRPC) on enzalutamide develops progressive disease with new liver metastases. He is switched to docetaxel plus prednisone. After 6 cycles, his PSA declines by 80% and liver lesions shrink, but he develops new-onset bilateral gynecomastia, mild hyperpigmentation of palmar creases, and worsening fatigue. Serum studies show: testosterone 12 ng/dL (low), LH 0.1 mIU/mL (low), FSH 0.2 mIU/mL (low), cortisol 4 mcg/dL (8 AM, low), ACTH 15 pg/mL (inappropriately normal), TSH 0.8 mIU/L, free T4 1.0 ng/dL. What is the most likely underlying mechanism for his new symptoms?", "options": ["Secondary adrenal insufficiency due to docetaxel-induced autoimmune hypophysitis", "Ectopic ACTH secretion from prostate cancer cells transforming to small cell neuroendocrine carcinoma", "Inhibition of CYP17A1 by residual enzalutamide leading to combined glucocorticoid and mineralocorticoid deficiency", "Docetaxel-induced primary testicular failure with subsequent feedback suppression of gonadotropins", "Paraneoplastic production of beta-hCG by treatment-emergent neuroendocrine-differentiated prostate cancer"], "answer": "C", "answer_index": 2, "explanation": "The clinical picture suggests combined glucocorticoid and androgen deficiency with low ACTH, consistent with secondary adrenal insufficiency due to central suppression. Enzalutamide is a potent androgen receptor inhibitor but also inhibits multiple CYP enzymes, including CYP17A1, which is required for glucocorticoid and androgen synthesis. When docetaxel suppresses tumor burden, residual enzalutamide (with a long half-life) continues to block adrenal steroidogenesis, causing a late-presenting adrenal crisis. Ectopic ACTH would elevate ACTH; autoimmune hypophysitis typically elevates TSH and causes other pituitary deficiencies; primary testicular failure elevates LH/FSH; beta-hCG causes gynecomastia but not adrenal insufficiency.", "generator_model": "deepseek-v3.2", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Medical Oncology", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: K (Miskeyed). Verdict: The keyed answer (C) is medically inaccurate; the correct answer is A. Key stem clues: new-onset symptoms after 6 cycles of docetaxel (gynecomastia, hyperpigmentation, fatigue), low cortisol (4 mcg/dL), inappropriately normal/low ACTH (15 pg/mL), low gonadotropins (LH 0.1, FSH 0.2), and low testosterone. These findings indicate secondary adrenal insufficiency with hypogonadotropic hypogonadism, classic for hypophysitis affecting both ACTH and gonadotropin axes. The ACTH of 15 pg/mL is inappropriately normal for severe hypocortisolism (should be >50-100), indicating pituitary dysfunction. Docetaxel-induced hypophysitis is well-documented. Option C is medically incorrect: enzalutamide does NOT inhibit CYP17A1 (abiraterone does); enzalutamide is a pure androgen receptor antagonist. The rationale confuses enzalutamide with abiraterone. CYP17A1 inhibition would cause primary adrenal insufficiency with elevated ACTH, not low ACTH. The patient was switched FROM enzalutamide TO docetaxel, so residual enzalutamide effect is implausible after 6 cycles. Main medical issue: fundamental error attributing CYP17A1 inhibition to enzalutamide. Minimal fix: Change key to A or rewrite vignette to include abiraterone instead of enzalutamide.\",\"medical_accuracy_score\":\"2\",\"logical_validity\":false,\"logical_false_reason\":\"K\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict: The keyed answer (C) is medically inaccurate; the correct answer is A. Key stem clues: new-onset symptoms after 6 cycles of docetaxel (gynecomastia, hyperpigmentation, fatigue), low cortisol (4 mcg/dL), inappropriately normal/low ACTH (15 pg/mL), low gonadotropins (LH 0.1, FSH 0.2), and low testosterone. These findings indicate secondary adrenal insufficiency with hypogonadotropic hypogonadism, classic for hypophysitis affecting both ACTH and gonadotropin axes. The ACTH of 15 pg/mL is inappropriately normal for severe hypocortisolism (should be >50-100), indicating pituitary dysfunction. Docetaxel-induced hypophysitis is well-documented. Option C is medically incorrect: enzalutamide does NOT inhibit CYP17A1 (abiraterone does); enzalutamide is a pure androgen receptor antagonist. The rationale confuses enzalutamide with abiraterone. CYP17A1 inhibition would cause primary adrenal insufficiency with elevated ACTH, not low ACTH. The patient was switched FROM enzalutamide TO docetaxel, so residual enzalutamide effect is implausible after 6 cycles. Main medical issue: fundamental error attributing CYP17A1 inhibition to enzalutamide. Minimal fix: Change key to A or rewrite vignette to include abiraterone instead of enzalutamide.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251216T183904770Z_deepseek-v3.2_seed131", "question_id": "20251216T183904770Z_deepseek-v3.2_seed131-002", "question": "A 32-year-old woman with common variable immunodeficiency (CVID) on monthly IVIG develops acute severe headache, photophobia, and neck stiffness 36 hours after her infusion. LP shows: opening pressure 28 cm H2O, WBC 2/μL, protein 40 mg/dL, glucose 60 mg/dL (serum 95 mg/dL). Gram stain and culture negative. MRI brain with contrast is normal. She has had two similar but milder episodes in the past 12 months, always within 48 hours of IVIG. Which intervention is most likely to prevent recurrence while maintaining adequate immune protection?", "options": ["Switch to subcutaneous immunoglobulin (SCIG) at the same monthly dose", "Pre‑infusion high‑dose corticosteroid (e.g., methylprednisolone 1 g IV)", "Change IVIG product to a sucrose‑free, low‑osmolality formulation", "Administer IVIG at a slower infusion rate (e.g., over 72 hours) with pre‑hydration", "Replace IVIG with prophylactic antibiotics and as‑needed plasma infusions"], "answer": "A", "answer_index": 0, "explanation": "This describes aseptic meningitis secondary to IVIG, a well‑known complication related to high peak IgG levels and cytokine release. Switching to SCIG provides steady‑state IgG levels without peaks, dramatically reducing meningitis risk while maintaining protection. Slower infusion or changing formulation may reduce but not eliminate risk in susceptible patients. Pre‑infusion steroids are not routinely effective and pose long‑term risks. Discontinuing immunoglobulin replacement in CVID would lead to serious infections despite antibiotics.", "generator_model": "deepseek-v3.2", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Allergy / Immunology", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V. Verdict: Correct best answer. The vignette describes recurrent aseptic meningitis temporally linked to IVIG infusions (within 48 hours, three episodes over 12 months). Key discriminating findings: (1) temporal relationship to IVIG, (2) sterile CSF with minimal pleocytosis, (3) elevated opening pressure, (4) normal MRI, (5) recurrent pattern. This classic presentation of IVIG-induced aseptic meningitis requires intervention to prevent recurrence while maintaining immune protection in CVID. Option A (SCIG) is the best answer because subcutaneous administration provides steady-state IgG levels without the high peaks associated with IV boluses, eliminating the primary mechanism (cytokine release from rapid IgG loading). This is well-established in literature as definitive management for recurrent IVIG-induced aseptic meningitis. Option B (corticosteroids) lacks evidence for prevention and adds immunosuppression risk. Option C (formulation change) may help but is less reliable than route change. Option D (slower infusion) reduces but doesn't eliminate peak levels. Option E (discontinue IVIG) is contraindicated in CVID. The item is logically valid with clear stem-to-answer pathway. Medical accuracy is excellent, reflecting current standard practice. No fix needed.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The vignette describes recurrent aseptic meningitis temporally linked to IVIG infusions (within 48 hours, three episodes over 12 months). Key discriminating findings: (1) temporal relationship to IVIG, (2) sterile CSF with minimal pleocytosis, (3) elevated opening pressure, (4) normal MRI, (5) recurrent pattern. This classic presentation of IVIG-induced aseptic meningitis requires intervention to prevent recurrence while maintaining immune protection in CVID. Option A (SCIG) is the best answer because subcutaneous administration provides steady-state IgG levels without the high peaks associated with IV boluses, eliminating the primary mechanism (cytokine release from rapid IgG loading). This is well-established in literature as definitive management for recurrent IVIG-induced aseptic meningitis. Option B (corticosteroids) lacks evidence for prevention and adds immunosuppression risk. Option C (formulation change) may help but is less reliable than route change. Option D (slower infusion) reduces but doesn't eliminate peak levels. Option E (discontinue IVIG) is contraindicated in CVID. The item is logically valid with clear stem-to-answer pathway. Medical accuracy is excellent, reflecting current standard practice. No fix needed.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251216T183904770Z_deepseek-v3.2_seed131", "question_id": "20251216T183904770Z_deepseek-v3.2_seed131-003", "question": "An 87‑year‑old man with moderate Alzheimer dementia (MoCA 14/30), hypertension, and chronic kidney disease (eGFR 28 mL/min/1.73m²) is admitted from assisted living for acute confusion and agitation. He has been on donepezil 10 mg daily for 3 years. In the ED, he receives lorazepam 1 mg IM for severe agitation, with minimal effect. Inpatient medications include amlodipine, losartan, and aspirin. Over 48 hours, he develops persistent non‑rhythmic myoclonic jerks of the face and limbs, fluctuating alertness, and autonomic instability (HR 110-140, BP 170/95). EEG shows generalized periodic discharges with triphasic morphology. MRI brain is unchanged from baseline (moderate atrophy). What is the most likely diagnosis?", "options": ["Creutzfeldt‑Jakob disease", "Serotonin syndrome from an undetected SSRI", "Donepezil toxicity in the setting of acute kidney injury", "Nonconvulsive status epilepticus due to underlying neurodegeneration", "Acute anticholinergic delirium from a newly started medication"], "answer": "C", "answer_index": 2, "explanation": "The presentation with myoclonus, autonomic instability, altered mental status, and triphasic waves on EEG in a patient on donepezil with advanced CKD suggests donepezil toxicity. Donepezil is renally excreted, and acute kidney injury (even mild) can precipitate toxicity. Triphasic waves are classically associated with metabolic/toxic encephalopathies, including acetylcholinesterase inhibitor toxicity. Creutzfeldt‑Jakob disease would show rapid progression and MRI diffusion abnormalities. Serotonin syndrome requires a serotonergic agent. Nonconvulsive status typically shows rhythmic epileptiform discharges. Anticholinergic delirium causes dry skin, not myoclonus or triphasic waves.", "generator_model": "deepseek-v3.2", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Geriatrics", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: K (Miskeyed). Verdict: Miskeyed - the keyed answer is not the best answer. Key stem clues: 87-year-old with moderate Alzheimer's on donepezil 10mg daily for 3 years, baseline CKD (eGFR 28), acute confusion/agitation, received lorazepam 1mg IM, develops myoclonus, fluctuating alertness, autonomic instability (HR 110-140, BP 170/95), EEG shows generalized periodic discharges with triphasic morphology. The stem states baseline eGFR is 28 mL/min/1.73m² (stage 4 CKD) but provides NO evidence of acute kidney injury or worsening renal function. The rationale assumes AKI occurred, but this is not stated. Donepezil toxicity (C) requires AKI superimposed on CKD, which is absent. The clinical picture - myoclonus, autonomic instability, altered mental status, triphasic waves - is classic for Creutzfeldt-Jakob disease (A), which can present acutely in elderly patients. While CJD typically shows MRI DWI abnormalities, early cases may have normal imaging. The absence of documented AKI makes C indefensible as written. Main logical issue: The keyed answer requires an unstated critical fact (AKI). Main medical issue: Misattribution of classic CJD features to donepezil toxicity without documented renal deterioration. Minimal fix: Add laboratory data showing acute rise in creatinine to support AKI and justify answer C.\", \"medical_accuracy_score\": \"3\", \"logical_validity\": false, \"logical_false_reason\": \"K\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict: Miskeyed - the keyed answer is not the best answer. Key stem clues: 87-year-old with moderate Alzheimer's on donepezil 10mg daily for 3 years, baseline CKD (eGFR 28), acute confusion/agitation, received lorazepam 1mg IM, develops myoclonus, fluctuating alertness, autonomic instability (HR 110-140, BP 170/95), EEG shows generalized periodic discharges with triphasic morphology. The stem states baseline eGFR is 28 mL/min/1.73m² (stage 4 CKD) but provides NO evidence of acute kidney injury or worsening renal function. The rationale assumes AKI occurred, but this is not stated. Donepezil toxicity (C) requires AKI superimposed on CKD, which is absent. The clinical picture - myoclonus, autonomic instability, altered mental status, triphasic waves - is classic for Creutzfeldt-Jakob disease (A), which can present acutely in elderly patients. While CJD typically shows MRI DWI abnormalities, early cases may have normal imaging. The absence of documented AKI makes C indefensible as written. Main logical issue: The keyed answer requires an unstated critical fact (AKI). Main medical issue: Misattribution of classic CJD features to donepezil toxicity without documented renal deterioration. Minimal fix: Add laboratory data showing acute rise in creatinine to support AKI and justify answer C.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251216T183904770Z_deepseek-v3.2_seed131", "question_id": "20251216T183904770Z_deepseek-v3.2_seed131-004", "question": "A 45‑year‑old woman with metastatic HER2‑positive breast cancer (bone, liver) on first‑line therapy with trastuzumab, pertuzumab, and docetaxel achieves a partial response after 6 cycles. Maintenance trastuzumab/pertuzumab is continued. One year later, surveillance CT shows a new 2 cm pancreatic tail mass, biopsy‑proven adenocarcinoma consistent with breast primary (ER‑/PR‑/HER2 3+ by IHC). Next‑generation sequencing of the pancreatic lesion reveals an activating mutation in PIK3CA (H1047R) and no HER2 amplification by NGS (though IHC remains 3+). She has never received a CDK4/6 inhibitor or everolimus. What is the most appropriate next systemic therapy?", "options": ["Continue trastuzumab/pertuzumab and add capecitabine", "Switch to trastuzumab deruxtecan (T‑DXd)", "Switch to lapatinib plus capecitabine", "Switch to everolimus plus exemestane", "Switch to alpelisib plus fulvestrant"], "answer": "B", "answer_index": 1, "explanation": "This represents HER2‑positive breast cancer with apparent HER2 discordance (IHC 3+ but no amplification by NGS) and acquired PIK3CA mutation. Trastuzumab deruxtecan (T‑DXd) is effective even in HER2‑low disease and has shown activity in HER2‑positive cancers resistant to trastuzumab/pertuzumab. Continuing dual HER2 blockade with chemotherapy is less likely to work given possible HER2‑negative clone emergence. Lapatinib/capecitabine is an older second‑line option but inferior to T‑DXd. Everolimus/exemestane or alpelisib/fulvestrant target hormone pathway/PIK3CA but are for HR‑positive disease; here the tumor is ER‑/PR‑.", "generator_model": "deepseek-v3.2", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Medical Oncology", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: M (Multiple answers defensible). Verdict: Not uniquely determinable. The vignette describes HER2-positive metastatic breast cancer progressing on trastuzumab/pertuzumab maintenance with a new pancreatic metastasis showing HER2 discordance (IHC 3+ but no amplification by NGS) and PIK3CA mutation. Key stem clues: progression on dual HER2 blockade, HER2 IHC 3+ maintained, ER-/PR-/HER2+, PIK3CA H1047R mutation, no prior CDK4/6i/everolimus. The keyed answer (B, T-DXd) is defensible as a potent HER2-directed ADC effective in HER2-low/resistant disease. However, option A (continue trastuzumab/pertuzumab + capecitabine) is equally defensible: IHC 3+ still qualifies as HER2-positive regardless of NGS amplification status; adding chemotherapy to continued HER2 blockade is standard second-line practice. The critical issue is HER2 status interpretation—IHC 3+ defines HER2-positivity by clinical guidelines even without amplification, making both HER2-directed strategies (A and B) reasonable. The PIK3CA mutation is a red herring since no PI3K inhibitor option applies to ER-/PR- disease. Main logical issue: the stem creates ambiguity about whether to treat as HER2-positive (favoring A or B) versus HER2-resistant (favoring B alone), allowing multiple defensible answers. Medical accuracy: both options align with guidelines. Minimal fix: clarify whether IHC 3+ without amplification should be treated as HER2-positive or specify prior chemotherapy exposure to eliminate option A.\", \"medical_accuracy_score\": \"4\", \"logical_validity\": false, \"logical_false_reason\": \"M\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: M (Multiple answers defensible). Verdict: Not uniquely determinable. The vignette describes HER2-positive metastatic breast cancer progressing on trastuzumab/pertuzumab maintenance with a new pancreatic metastasis showing HER2 discordance (IHC 3+ but no amplification by NGS) and PIK3CA mutation. Key stem clues: progression on dual HER2 blockade, HER2 IHC 3+ maintained, ER-/PR-/HER2+, PIK3CA H1047R mutation, no prior CDK4/6i/everolimus. The keyed answer (B, T-DXd) is defensible as a potent HER2-directed ADC effective in HER2-low/resistant disease. However, option A (continue trastuzumab/pertuzumab + capecitabine) is equally defensible: IHC 3+ still qualifies as HER2-positive regardless of NGS amplification status; adding chemotherapy to continued HER2 blockade is standard second-line practice. The critical issue is HER2 status interpretation—IHC 3+ defines HER2-positivity by clinical guidelines even without amplification, making both HER2-directed strategies (A and B) reasonable. The PIK3CA mutation is a red herring since no PI3K inhibitor option applies to ER-/PR- disease. Main logical issue: the stem creates ambiguity about whether to treat as HER2-positive (favoring A or B) versus HER2-resistant (favoring B alone), allowing multiple defensible answers. Medical accuracy: both options align with guidelines. Minimal fix: clarify whether IHC 3+ without amplification should be treated as HER2-positive or specify prior chemotherapy exposure to eliminate option A.", "medical_accuracy_score": 4, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251216T183904770Z_deepseek-v3.2_seed131", "question_id": "20251216T183904770Z_deepseek-v3.2_seed131-005", "question": "A 28‑year‑old woman with idiopathic anaphylaxis presents with recurrent episodes of urticaria, angioedema, wheezing, and hypotension occurring 2-3 times monthly despite high‑dose antihistamines and montelukast. She undergoes exhaustive evaluation: normal tryptase, negative specific IgE to foods/venoms/drugs, no mastocytosis on bone marrow biopsy, and no physical urticaria triggers. During a supervised oral challenge to placebo in clinic, she develops identical symptoms with hypotension. Serum collected during the event shows elevated prostaglandin D2 (PGD2) but normal histamine and tryptase. Which therapy is most likely to be effective in preventing future episodes?", "options": ["Omalizumab (anti‑IgE)", "Rituximab (anti‑CD20)", "Imatinib (tyrosine kinase inhibitor)", "Continuous intravenous epinephrine infusion", "NSAID (e.g., indomethacin) prior to suspected triggers"], "answer": "E", "answer_index": 4, "explanation": "Elevated PGD2 with normal histamine/tryptase during symptoms suggests a prostaglandin‑mediated disorder, possibly a mast cell activation syndrome variant or idiopathic flush‑related anaphylaxis. NSAIDs inhibit cyclooxygenase and reduce PGD2 production, which can prevent episodes in select patients with prostaglandin‑driven symptoms. Omalizumab targets IgE‑mediated pathways, not primarily prostaglandin‑mediated. Rituximab is for autoimmune conditions. Imatinib is for mastocytosis with KIT mutations. Continuous epinephrine is not a preventive therapy and carries high risk.", "generator_model": "deepseek-v3.2", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Allergy / Immunology", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: M (Multiple answers defensible). Verdict: Not uniquely determinable. The stem describes recurrent anaphylaxis with elevated PGD2 but normal histamine/tryptase during a placebo-triggered event, suggesting non-IgE-mediated mast cell activation. Key discriminating findings: (1) idiopathic anaphylaxis refractory to antihistamines/montelukast, (2) negative workup for IgE-mediated causes, (3) symptoms triggered by placebo (psychogenic component?), (4) elevated PGD2 with normal histamine/tryptase. The keyed answer (E, NSAIDs) assumes prostaglandin-mediated pathology where COX inhibition would help. However, omalizumab (A) has established efficacy in refractory chronic urticaria and idiopathic anaphylaxis, including cases without clear IgE mechanisms, through effects on mast cell stabilization beyond simple anti-IgE activity. Both A and E are defensible: omalizumab has stronger evidence base for refractory mast cell-mediated disease, while NSAIDs theoretically target PGD2 but lack robust trial data for this indication and carry risks (paradoxical reactions in some patients). The placebo-triggered event further complicates causality. Medical accuracy issue: NSAIDs can paradoxically worsen urticaria/anaphylaxis in susceptible individuals; recommending them as first-line prevention is questionable. Minimal fix: Clarify that omalizumab failed or specify a validated prostaglandin-mediated syndrome where NSAIDs are standard.\",\"medical_accuracy_score\":\"3\",\"logical_validity\":false,\"logical_false_reason\":\"M\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: M (Multiple answers defensible). Verdict: Not uniquely determinable. The stem describes recurrent anaphylaxis with elevated PGD2 but normal histamine/tryptase during a placebo-triggered event, suggesting non-IgE-mediated mast cell activation. Key discriminating findings: (1) idiopathic anaphylaxis refractory to antihistamines/montelukast, (2) negative workup for IgE-mediated causes, (3) symptoms triggered by placebo (psychogenic component?), (4) elevated PGD2 with normal histamine/tryptase. The keyed answer (E, NSAIDs) assumes prostaglandin-mediated pathology where COX inhibition would help. However, omalizumab (A) has established efficacy in refractory chronic urticaria and idiopathic anaphylaxis, including cases without clear IgE mechanisms, through effects on mast cell stabilization beyond simple anti-IgE activity. Both A and E are defensible: omalizumab has stronger evidence base for refractory mast cell-mediated disease, while NSAIDs theoretically target PGD2 but lack robust trial data for this indication and carry risks (paradoxical reactions in some patients). The placebo-triggered event further complicates causality. Medical accuracy issue: NSAIDs can paradoxically worsen urticaria/anaphylaxis in susceptible individuals; recommending them as first-line prevention is questionable. Minimal fix: Clarify that omalizumab failed or specify a validated prostaglandin-mediated syndrome where NSAIDs are standard.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251216T183904770Z_deepseek-v3.2_seed131", "question_id": "20251216T183904770Z_deepseek-v3.2_seed131-006", "question": "An 82‑year‑old woman with aortic stenosis (mean gradient 38 mm Hg, AVA 0.9 cm²), COPD (FEV1 45%), and stage 3 CKD is admitted with syncope. She lives independently but reports declining energy over 6 months. She is evaluated by cardiology and deemed high risk for surgical AVR but a candidate for TAVR. During shared decision‑making, which factor, if present, would most strongly argue against proceeding with TAVR?", "options": ["Recent fall with subdural hematoma requiring reversal of apixaban 3 months ago", "Moderate‑severe mitral regurgitation due to annular dilation", "Life expectancy estimated at less than 12 months due to metastatic lung cancer diagnosed 2 months ago", "Frailty score consistent with slow gait and low grip strength but able to perform ADLs", "Asymptomatic 4 cm abdominal aortic aneurysm noted on pre‑TAVR CT"], "answer": "C", "answer_index": 2, "explanation": "TAVR is indicated to improve quality of life and survival in patients with severe symptomatic aortic stenosis whose life expectancy is >12 months. A life expectancy <12 months due to metastatic cancer makes the procedural risks and recovery burdens unjustifiable. Recent subdural hematoma is a relative contraindication but may be timed. Moderate‑severe MR often improves post‑TAVR. Frailty alone does not preclude TAVR if the patient can participate in rehabilitation. A 4 cm AAA is below threshold for repair and not a contraindication.", "generator_model": "deepseek-v3.2", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Geriatrics", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V. Verdict: Correct best answer. The stem describes an 82-year-old with severe symptomatic aortic stenosis (mean gradient 38 mmHg, AVA 0.9 cm²) and syncope, deemed high-risk for surgical AVR but a TAVR candidate. The question asks which factor most strongly argues against TAVR. Key discriminating finding: Option C presents metastatic lung cancer with life expectancy <12 months. TAVR guidelines consistently state that the procedure is indicated when life expectancy exceeds 12 months, as the intervention aims to improve both quality of life and survival. With life expectancy <12 months from non-cardiac disease, procedural risks and recovery burden cannot be justified. Option A (subdural hematoma 3 months prior) is a relative contraindication that can be managed with timing. Option B (moderate-severe MR) often improves post-TAVR and is not an absolute contraindication. Option D (frailty with preserved ADLs) does not preclude TAVR if rehabilitation is feasible. Option E (4 cm AAA) is below intervention threshold and irrelevant to TAVR candidacy. The keyed answer C is medically accurate and uniquely defensible as the strongest contraindication. No logical flaws or medical inaccuracies identified. Minimal fix: None needed.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The stem describes an 82-year-old with severe symptomatic aortic stenosis (mean gradient 38 mmHg, AVA 0.9 cm²) and syncope, deemed high-risk for surgical AVR but a TAVR candidate. The question asks which factor most strongly argues against TAVR. Key discriminating finding: Option C presents metastatic lung cancer with life expectancy <12 months. TAVR guidelines consistently state that the procedure is indicated when life expectancy exceeds 12 months, as the intervention aims to improve both quality of life and survival. With life expectancy <12 months from non-cardiac disease, procedural risks and recovery burden cannot be justified. Option A (subdural hematoma 3 months prior) is a relative contraindication that can be managed with timing. Option B (moderate-severe MR) often improves post-TAVR and is not an absolute contraindication. Option D (frailty with preserved ADLs) does not preclude TAVR if rehabilitation is feasible. Option E (4 cm AAA) is below intervention threshold and irrelevant to TAVR candidacy. The keyed answer C is medically accurate and uniquely defensible as the strongest contraindication. No logical flaws or medical inaccuracies identified. Minimal fix: None needed.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}]